Team

Luc Koldewyn graduated with a bachelors in biology from Colorado State University in 2009. He began his medical career as an assistant to Dr. E. Jeffrey Donner in 2009 with Rocky Mountain Associates in Orthopedic Medicine (RMA). Through his experience with RMA, he gained knowledge assisting several physicians in spine treatment, orthopedic treatments, interventional pain, manual manipulation, and regenerative medicine. Continuing education Luc was involved as an EMT, assisting in procedures and became more involved in the OR for spine procedures where he was a medical hardware representative.

Luc and Dr. Donner began development of the stem cell program in 2015 where they took their combined knowledge to develop the Elite Regenerative Stem Cell Specialists. Luc has been the program coordinator and assistant director, continuing the advancement of the business and science. Luc is active in the onsite medical laboratory, developing medical devices, and continued research in the field of regenerative medicine.

Luc has a personal connection with bio-cellular treatment. In 2011 he acquired an injury to his lower back while harvesting hay. The MRI indicated a 6mm herniation and degenerative disc disease. After conservative treatment failed, the only option was a lumbar fusion at L5-S1. He opted for a stem cell treatment which regenerated his disc and he has been pain free ever since.

Dr. Sealy Hambright Joined us from the Linda and Mitch Hart Center for Regenerative and Personalized Medicine (CRPM) at the Steadman Philippon Research Institute (SPRI). At SPRI, he served as a Principal Investigator and Program where he developed strategies that target fundamental properties of aging including senescent (aged) cell accumulation, telomere erosion, and inflammation to improve orthoregenerative medicine therapies. As a Program Director at SPRI, he also designed or co-designed multiple clinical studies using senolytic drugs to improve functional orthopedic outcomes. This includes several NIH/DoD sponsored (Hambright, Co-I) interventional trials using senolytics to improve orthobiologic therapy in the setting of OA and femoroacetabular impingement/labral tears (NCT03675724, NCT04210986, NCT04815902, NCT04205656). Collectively, these trials contain diverse outcome measures that encompass functional performance, patient reported pain and mobility, advanced MRI analysis, and measurement of biomarkers from multiple biospecimen types.

Dr. Hambright received his BS in Biology from the University of Dr. Sealy Hambright received his B.S. in Biology from the University of Texas at Tyler. He then completed his M.S. in Microbiology at the University of Texas at Arlington prior to completing his PhD training in the Biology of Aging Training Program at UTHealth San Antonio at the Barshop Institute for Longevity and Aging Studies. As a PhD student under Qitao Ran, he investigated the redox biology of age associated neurodegenerative diseases including mechanisms related to cognitive decline. He and his colleagues were the first to identify ferroptosis as a novel cell-death mechanism responsible for degeneration of neurons primarily afflicted during ALS and Alzheimer’s disease. His work elucidating these mechanisms in different neuronal populations has garnered over 500 citations from two different manuscripts.

Currently Dr. Hambright owns and operates Hambright Consulting. He is also the Chief Scientific Officer of TriCelX Bio, a biopharma startup focused on bioaesthetics, orthobiologics, and MSC based therapeutics.